Key clinical point: Unintentional transduction of a single leukemic B cell induced resistance to CTL019 (tisagenlecleucel) therapy.
Major finding: A patient with B-cell acute lymphoblastic leukemia (B-ALL) had frank relapse 9 months after a CTL019 infusion, with more than 90% bone marrow infiltration of chimeric antigen receptor–transduced B-cell leukemia cells.
Study details: A case study of a 20-year-old male with B-ALL undergoing CTL019 therapy.
Disclosures: Study funding was provided by Bristol-Myers Squibb, Novartis, the National Institutes of Health, and others. Dr. Ruella and several of his colleagues work under a research collaboration involving the University of Pennsylvania and the Novartis Institutes of Biomedical Research and are inventors of intellectual property licensed by the University of Pennsylvania to Novartis.
Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9.
This Week's Must Reads
Long-term data on R-CHOP in follicular lymphoma, Wantanabe T et al. Lancet Haematol. 2018 Nov;5(11):e520-31
Bortezomib looks promising in WM mutations, Sklavenitis-Pistofidis R et al. Blood. 2018 Oct 26. doi: 10.1182/blood-2018-07-863241
Patient perspectives on NHL treatment, Chircop D et al. Eur J Oncol Nurs. 2018 Aug;35:117-21
Positive results for rituximab biosimilar in comparative trial, Ogura M et al. Lancet Haematol. 2018 Nov;5(11):e543-53
Patient blood management in stem cell transplant, Jambhekar N et al. AABB 2018, Abstract PBM3-ST4-22
Must Reads in Leukemia, Myelodysplasia, Transplantation
CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9
New Choosing Wisely Guidance on BMT Released , Biol Blood Marrow Transplant; ePub 2018 Jan 19; Bhella, et al
Second Primary Malignancies in Patients with MM, Biol Blood Marrow Transplant; ePub 2018 Jan 12; Sahebi, et al
Progression to MM in Patients with MGUS Assessed, N Engl J Med; 2018 Jan 18; Kyle, Larson, et al
These 2 Markers May Impact MGUS Progression to MM , Leuk Lymphoma; ePub 2018 Jan 18; Vallet, et al